経口タンパク質・ペプチド市場：薬剤タイプ別、用途別-2025-2030年の世界予測

経口タンパク質・ペプチド市場は、2023年に14億米ドルと評価され、2024年には15億9,000万米ドルに達すると予想され、CAGR 13.37％で成長し、2030年には33億8,000万米ドルになると予測されています。

経口タンパク質・ペプチド市場には、経口経路で送達されるタンパク質・ペプチドベースの治療薬の開発と商業化が含まれます。この市場を牽引しているのは、糖尿病、がん、骨粗鬆症などの慢性疾患に対処する必要性であり、経口投与によって患者のコンプライアンスと治療効果を大幅に高めることができます。適用範囲には、従来は注射によって投与されていたペプチドが、ドラッグデリバリー技術の進歩によって経口摂取用に改良された薬理学的治療が含まれます。最終用途は、製薬会社やバイオテクノロジー企業、研究機関、受託研究機関を主な対象としており、経口投与生物製剤の需要拡大を狙っています。

この市場の重要な成長要因には、ナノテクノロジーと経口ドラッグデリバリーシステムの進歩が含まれ、タンパク質とペプチドのバイオアベイラビリティと安定性の向上が可能になります。長期的な治療レジメンを必要とする慢性疾患の有病率の増加は、市場拡大の大きなチャンスとなります。さらに、新規の経口生物製剤を市場に投入するために、大手製薬企業による研究開発（R&D）への投資が増加していることも注目に値します。こうした機会を最大限に生かすため、企業は共同研究開発のための提携や共同研究に投資すべきです。

しかし、市場の成長は、消化管での分解や吸収率の変動による高い経口バイオアベイラビリティを達成するための固有の課題などの制約によって制限されています。さらに、バイオ治療薬の承認に関連する規制の複雑さも、進展の妨げになる可能性があります。これらのハードルを克服するために、業界はより安定したタンパク質構造の設計、プロテアーゼ阻害剤の利用、新規賦形剤や製剤技術の開発といった革新的な分野に注力することができます。

市場は進歩的な性質を示し、患者中心のソリューションを強化する破壊的イノベーションの可能性が大きいです。個別化医療への関心の高まりが、より的を絞った効果的な経口ペプチド治療薬の創出に向けた研究開発の推進力となっていることが示唆されます。企業は、競争力を確立し効率的に事業を成長させるために、経口投与プロセスの最適化と未開拓市場の開拓に注力すべきです。

市場力学：急速に進化する経口タンパク質・ペプチド市場における主要市場インサイトの解明

経口タンパク質・ペプチド市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の増加
  • 経口薬に対する患者の嗜好の高まり
  • タンパク質やペプチドの経口投与に必要な材料の十分な入手可能性
• 市場抑制要因
  • 経口ペプチドの高い製造コスト
• 市場機会
  • 経口デリバリー用ナノ粒子の出現
  • 製薬会社による研究開発の増加
• 市場の課題
  • 不要な酵素分解や固有の構造の複雑さに関する懸念

ポーターの5つの力：経口タンパク質・ペプチド市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：経口タンパク質・ペプチド市場における外部からの影響の把握

外部マクロ環境要因は、経口タンパク質・ペプチド市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析経口タンパク質・ペプチド市場における競合情勢の把握

経口タンパク質・ペプチド市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス経口タンパク質・ペプチド市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、経口タンパク質・ペプチド市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨経口タンパク質・ペプチド市場における成功への道筋を描く

経口タンパク質・ペプチド市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の罹患率の増加
    • 経口薬を好む患者の増加
    • タンパク質やペプチドの経口投与に適した材料の十分な入手可能性
  • 抑制要因
    • 経口ペプチドの高製造コスト
  • 機会
    • 経口投与用ナノ粒子の出現
    • 製薬会社の研究開発の増加
  • 課題
    • 望ましくない酵素分解と固有の構造の複雑さに関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 経口タンパク質・ペプチド市場薬の種類別

• カルシトニン
• インスリン
• リナクロチド
• オクトレオチド
• プレカナチド

第7章 経口タンパク質・ペプチド市場：用途別

• 骨疾患
• 糖尿病
• 胃および消化器疾患
• ホルモン障害

第8章 南北アメリカの経口タンパク質・ペプチド市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の経口タンパク質・ペプチド市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの経口タンパク質・ペプチド市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Almac Group
• Astellas Pharma Inc.
• AstraZeneca PLC
• Biocon Limited
• Catalent, Inc.
• Chiasma, Inc.
• Eli Lilly and Company
• Merck KGaA
• Novartis AG
• Novo Nordisk A/S
• Oramed Pharmaceuticals Inc.
• Pfizer, Inc.
• Proxima Concepts Limited
• Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. ORAL PROTEINS & PEPTIDES MARKET RESEARCH PROCESS
• FIGURE 2. ORAL PROTEINS & PEPTIDES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ORAL PROTEINS & PEPTIDES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ORAL PROTEINS & PEPTIDES MARKET DYNAMICS
• TABLE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LINACLOTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PLECANATIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY BONE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GASTRIC & DIGESTIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 26. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 28. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 36. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 42. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 44. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 48. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 50. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 52. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 56. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 58. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 62. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 65. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 67. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 71. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 73. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 77. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 79. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 83. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 85. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 87. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 95. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 99. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 101. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 103. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 105. ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2023

The Oral Proteins & Peptides Market was valued at USD 1.40 billion in 2023, expected to reach USD 1.59 billion in 2024, and is projected to grow at a CAGR of 13.37%, to USD 3.38 billion by 2030.

The oral proteins and peptides market encompasses the development and commercialization of protein and peptide-based therapeutics delivered via the oral route. This market is driven by the necessity to address chronic diseases such as diabetes, cancer, and osteoporosis, where oral delivery can significantly enhance patient compliance and therapeutic effectiveness. The application scope includes pharmacological treatments where peptides, traditionally administered through injections, are reformulated for oral ingestion thanks to advancements in drug delivery technologies. The end-use spectrum predominantly targets pharmaceutical and biotechnology companies, research institutes, and contract research organizations, aiming to tap into the growing demand for orally administered biologics.

Critical growth factors in this market include advancements in nanotechnology and oral drug delivery systems, enabling better bioavailability and stability of proteins and peptides. The increasing prevalence of chronic diseases requiring long-term treatment regimens presents substantial opportunities for market expansion. Additionally, increasing investments in research and development (R&D) by major pharmaceutical companies to bring novel oral biologics to market are noteworthy. Companies should invest in partnerships and collaborations for co-research and development to maximize these opportunities.

However, market growth is restricted by limitations such as the inherent challenges in achieving high oral bioavailability due to degradation in the gastrointestinal tract and variable absorption. Furthermore, regulatory complexities associated with the approval of biotherapeutics may also impede progress. To overcome these hurdles, the industry can focus on innovative areas such as designing more stable protein structures, utilizing protease inhibitors, and developing novel excipients and formulation technologies.

The market exhibits a progressive nature, with significant potential for disruptive innovations that enhance patient-centric solutions. Insights suggest a growing interest in personalized medicine, which is driving R&D towards creating more targeted and effective oral peptide therapies. Businesses should focus on optimizing the oral delivery process and exploring untapped markets to establish a competitive edge and foster business growth effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oral Proteins & Peptides Market

The Oral Proteins & Peptides Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in prevalence of chronic diseases
  • Rise in patient preference for oral drugs
  • Adequate availability of materials for oral delivery of proteins and peptides
• Market Restraints
  • High manufacturing costs of oral peptides
• Market Opportunities
  • Emergence of nanoparticles for oral delivery
  • Increase in R&D by pharmaceutical companies
• Market Challenges
  • Concerns related to unwanted enzymatic degradation and inherent structural complexities

Porter's Five Forces: A Strategic Tool for Navigating the Oral Proteins & Peptides Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oral Proteins & Peptides Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oral Proteins & Peptides Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oral Proteins & Peptides Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oral Proteins & Peptides Market

A detailed market share analysis in the Oral Proteins & Peptides Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oral Proteins & Peptides Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oral Proteins & Peptides Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oral Proteins & Peptides Market

A strategic analysis of the Oral Proteins & Peptides Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oral Proteins & Peptides Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Almac Group, Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Catalent, Inc., Chiasma, Inc., Eli Lilly and Company, Merck KGaA, Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer, Inc., Proxima Concepts Limited, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Oral Proteins & Peptides Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Calcitonin, Insulin, Linaclotide, Octreotide, and Plecanatide.
• Based on Application, market is studied across Bone Diseases, Diabetes, Gastric & Digestive Disorders, and Hormonal Disorders.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in prevalence of chronic diseases
    • 5.1.1.2. Rise in patient preference for oral drugs
    • 5.1.1.3. Adequate availability of materials for oral delivery of proteins and peptides
  • 5.1.2. Restraints
    • 5.1.2.1. High manufacturing costs of oral peptides
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of nanoparticles for oral delivery
    • 5.1.3.2. Increase in R&D by pharmaceutical companies
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns related to unwanted enzymatic degradation and inherent structural complexities
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oral Proteins & Peptides Market, by Drug Type

• 6.1. Introduction
• 6.2. Calcitonin
• 6.3. Insulin
• 6.4. Linaclotide
• 6.5. Octreotide
• 6.6. Plecanatide

7. Oral Proteins & Peptides Market, by Application

• 7.1. Introduction
• 7.2. Bone Diseases
• 7.3. Diabetes
• 7.4. Gastric & Digestive Disorders
• 7.5. Hormonal Disorders

8. Americas Oral Proteins & Peptides Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Oral Proteins & Peptides Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Oral Proteins & Peptides Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Almac Group
• 3. Astellas Pharma Inc.
• 4. AstraZeneca PLC
• 5. Biocon Limited
• 6. Catalent, Inc.
• 7. Chiasma, Inc.
• 8. Eli Lilly and Company
• 9. Merck KGaA
• 10. Novartis AG
• 11. Novo Nordisk A/S
• 12. Oramed Pharmaceuticals Inc.
• 13. Pfizer, Inc.
• 14. Proxima Concepts Limited
• 15. Sanofi S.A.